BCLI$0.580
Chart
Performance
Key Stats
AI BCLI Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
SellBrainstorm Cell Therapeutics Inc. presents significant thematic potential in neurodegenerative disease treatments but faces substantial fundamental challenges, including negative profitability, high cash burn, and a deteriorating financial position. Technical indicators are mixed but lean negative in the medium to long term. Investors should exercise extreme caution.
Thematic
Brainstorm Cell Therapeutics is focused on developing cell therapies for neurodegenerative diseases like ALS, MS, and Alzheimer's. The underlying market for effective treatments in these areas is substantial and growing, offering significant potential if the company's therapies prove successful.
Fundamental
The company exhibits critical fundamental weaknesses, including zero revenue, substantial net losses, negative equity, significant debt relative to its market cap, and consistently negative free cash flow. The financial position is precarious.
Technical
The stock price has experienced extreme volatility and a significant decline over the past year. While there's been a recent short-term uptick, the overall trend and key technical indicators suggest weakness.
| Factor | Score |
|---|---|
| Neurodegenerative Disease Market | 90 |
| NurOwn Technology Platform | 85 |
| Competitive Landscape | 60 |
| Regulatory Pathway | 70 |
| Biotechnology Innovation Trend | 70 |
| Factor | Score |
|---|---|
| Valuation | 0 |
| Profitability | 0 |
| Growth | 0 |
| Balance Sheet Health | 5 |
| Cash Flow | 10 |
| Debt Management | 15 |
| Factor | Score |
|---|---|
| Trend Analysis | 20 |
| Momentum | 25 |
| Moving Averages | 15 |
| Volume | 60 |
| Support/Resistance | 40 |
AI Investing Checklist
Powered by LiveAIBullish Points (5)
EPS Beat and Improvement
Recent EPS estimates have been consistently beaten, with the latest quarter (2025 Q2) showing an actual EPS of -0.45, significantly better than the estimate of -0.97. This indicates a positive earnings trend.
Short-Term Price Momentum
The stock has shown a positive 5-day performance of 7.46%, suggesting recent positive investor sentiment and upward price movement.
Bearish Points (9)
Negative Earnings and No P/E
The company has negative EPS (TTM: -2.01) and no positive Price-to-Earnings (P/E) ratio, indicating the company is not currently profitable on a per-share basis. The market cap is small, suggesting a highly speculative investment.
Significant Long-Term Decline
The stock has experienced substantial declines over multiple periods: -32.08% (1M), -64.53% (6M), -66.36% (YTD), and -85.88% (1Y), indicating significant negative market sentiment and investor losses.
Calendar
August 2025
15
Next Earnings Date
H: $-0.33
A: $-0.33
L: $-0.33
Profile
Brainstorm Cell Therapeutics Inc. a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company's NurOwn proprietary cell therapy platform that leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is involved in the development of NurOwn, which has completed Phase IIIb clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for treatment of other neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.
Seasonals
Price Target
20.68 USD
The 39 analysts offering 1 year price forecasts for BCLI have a max estimate of 24.35 and a min estimate of 17.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Cash Flow
Related Companies
Powered by LiveAIWeight: 95
A leading biotechnology company focused on developing and commercializing therapies for rare diseases, particularly cystic fibrosis, aligning with BCLI's rare disease focus.
Weight: 90
A pure-play biopharmaceutical company dedicated to developing novel therapies for rare and ultra-rare genetic diseases, directly competing in the orphan drug space.
Weight: 90
An established leader in the development and commercialization of innovative therapies for rare genetic diseases, with a strong commercial presence.
Weight: 88
Focuses on developing and commercializing advanced therapies for rare metabolic diseases, often utilizing small molecule approaches.